{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,17]],"date-time":"2025-09-17T14:42:58Z","timestamp":1758120178295,"version":"3.28.0"},"reference-count":38,"publisher":"Georg Thieme Verlag KG","issue":"07\/08","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Fortschr Neurol Psychiatr"],"published-print":{"date-parts":[[2024,7]]},"abstract":"<jats:title>Zusammenfassung<\/jats:title><jats:p>Calcitonin Gene-related Peptide (CGRP) spielt eine zentrale Rolle in der\n                    Pathophysiologie der Migr\u00e4ne. Die Bedeutung von CGRP f\u00fcr die Migr\u00e4ne ist aus\n                    zahlreichen klinischen Studien mit Nachweis von erh\u00f6hten CGRP-Spiegeln iktal und\n                    interiktal sowie der Wirksamkeit der CGRP-basierten Therapien bekannt. In der\n                    vorliegenden Arbeit werden diese Studien vorgestellt und so der Weg zur\n                    Entwicklung der CGRP-basierten Medikamente aufgezeigt. Abschlie\u00dfend werden\n                    aktuelle Studienergebnisse in Bezug auf die CGRP-Rezeptorantagonisten, die\n                    sogenannten Gepante, vorgestellt.<\/jats:p>","DOI":"10.1055\/a-2331-0783","type":"journal-article","created":{"date-parts":[[2024,7,18]],"date-time":"2024-07-18T22:30:26Z","timestamp":1721341826000},"page":"267-276","source":"Crossref","is-referenced-by-count":1,"title":["CGRP: vom Neuropeptid zum therapeutischen Target (Hintergr\u00fcnde und\n                    Pathophysiologie)"],"prefix":"10.1055","volume":"92","author":[{"given":"Katharina","family":"Kamm","sequence":"additional","affiliation":[{"name":"Neurologische Klinik und Poliklinik, LMU Klinikum Campus\n                    Grosshadern, Ludwig-Maximilians-Universit\u00e4t M\u00fcnchen, M\u00fcnchen,\n                    Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"194","published-online":{"date-parts":[[2024,7,18]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1152\/physrev.00059.2021","article-title":"CGRP physiology, pharmacology, and therapeutic targets: migraine and beyond","volume":"103","author":"A F Russo","year":"2023","journal-title":"Physiological reviews"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1152\/physrev.00034.2013","article-title":"Calcitonin gene-related peptide: physiology and pathophysiology","volume":"94","author":"F A Russell","year":"2014","journal-title":"Physiological reviews"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/s00482-020-00448-y","article-title":"Bedeutung des \u201ecalcitonin gene-related peptide\u201c (CGRP) in der Pathophysiologie\n                    von Migr\u00e4ne und Clusterkopfschmerz","volume":"34","author":"K Me\u00dflinger","year":"2020","journal-title":"Der Schmerz"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/j.neurol.2021.06.003","article-title":"CGRP and migraine: from bench to bedside","volume":"177","author":"L Edvinsson","year":"2021","journal-title":"Revue neurologique"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s10194-018-0848-0","article-title":"The big CGRP flood-sources, sinks and signalling sites in the trigeminovascular\n                    system","volume":"19","author":"K Messlinger","year":"2018","journal-title":"The Journal of Headache and Pain"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"5731","DOI":"10.1073\/pnas.83.15.5731","article-title":"Calcitonin gene-related peptide: functional role in cerebrovascular\n                    regulation","volume":"83","author":"J McCulloch","year":"1986","journal-title":"Proceedings of the National Academy of Sciences"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1038\/s41582-018-0003-1","article-title":"CGRP as the target of new migraine therapies \u2013 successful translation from bench\n                    to clinic","volume":"14","author":"L Edvinsson","year":"2018","journal-title":"Nature Reviews Neurology"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1002\/ana.410280213","article-title":"Vasoactive peptide release in the extracerebral circulation of humans during\n                    migraine headache","volume":"28","author":"P Goadsby","year":"1990","journal-title":"Annals of Neurology: Official Journal of the American Neurological\n                    Association and the Child Neurology Society"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1002\/ana.410330109","article-title":"The trigeminovascular system and migraine: studies characterizing\n                    cerebrovascular and neuropeptide changes seen in humans and cats","volume":"33","author":"P J Goadsby","year":"1993","journal-title":"Annals of Neurology: Official Journal of the American Neurological\n                    Association and the Child Neurology Society"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1046\/j.1468-29821995.1505384.x","article-title":"Vasoactive peptide levels in the plasma of young migraine patients with and\n                    without aura assessed both interictally and ictally","volume":"15","author":"V Gallai","year":"1995","journal-title":"Cephalalgia"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1111\/j.1468-2982.2005.00836.x","article-title":"Sumatriptan causes parallel decrease in plasma calcitonin gene-related peptide\n                    (CGRP) concentration and migraine headache during nitroglycerin induced migraine\n                    attack","volume":"25","author":"G Juh\u00e1sz","year":"2005","journal-title":"Cephalalgia"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.pain.2003.09.008","article-title":"NO-induced migraine attack: strong increase in plasma calcitonin gene-related\n                    peptide (CGRP) concentration and negative correlation with platelet serotonin\n                    release","volume":"106","author":"G Juhasz","year":"2003","journal-title":"Pain"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1111\/j.1468-2982.2005.01016.x","article-title":"Clinical-biochemical correlates of migraine attacks in rizatriptan responders\n                    and non-responders","volume":"26","author":"P Sarchielli","year":"2006","journal-title":"Cephalalgia"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/S0304-3959(00)00232-3","article-title":"Evidence for increased plasma levels of calcitonin gene-related peptide in\n                    migraine outside of attacks","volume":"86","author":"M Ashina","year":"2000","journal-title":"Pain."},{"key":"ref18","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1212\/WNL.0b013e3182a6cb72","article-title":"Interictal increase of CGRP levels in peripheral blood as a biomarker for\n                    chronic migraine","volume":"81","author":"E Cernuda-Moroll\u00f3n","year":"2013","journal-title":"Neurology"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1111\/head.13211","article-title":"CGRP and PTX3 as predictors of efficacy of Onabotulinumtoxin type a in chronic\n                    migraine: an observational study","volume":"58","author":"C Dom\u00ednguez","year":"2018","journal-title":"Headache: The Journal of Head and Face Pain"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.pain.2006.09.017","article-title":"Increased plasma substance P and CGRP levels, and high ACE activity in\n                    migraineurs during headache-free periods","volume":"128","author":"E Fusayasu","year":"2007","journal-title":"Pain"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1186\/s10194-018-0883-x","article-title":"Feasibility of serum CGRP measurement as a biomarker of chronic migraine: a\n                    critical reappraisal","volume":"19","author":"M J Lee","year":"2018","journal-title":"The journal of headache and pain"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"7125","DOI":"10.1007\/s11033-020-05781-0","article-title":"Serum CGRP, VIP, and PACAP usefulness in migraine: a case \u2013 control study in\n                    chronic migraine patients in real clinical practice","volume":"47","author":"S P\u00e9rez-Pereda","year":"2020","journal-title":"Molecular Biology Reports"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"e1825","DOI":"10.1212\/WNL.0000000000207114","article-title":"Sex hormones and calcitonin gene-related peptide in women with migraine: a\n                    cross-sectional, matched cohort study","volume":"100","author":"B Raffaelli","year":"2023","journal-title":"Neurology"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1212\/WNL.0b013e31826170ce","article-title":"Endothelial progenitor cells: a new key for endothelial dysfunction in\n                    migraine","volume":"79","author":"X Rodr\u00edguez-Osorio","year":"2012","journal-title":"Neurology"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1002\/ana.20605","article-title":"No increase of calcitonin gene-related peptide in jugular blood during\n                    migraine","volume":"58","author":"J F Tvedskov","year":"2005","journal-title":"Annals of Neurology: Official Journal of the American Neurological\n                    Association and the Child Neurology Society"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1177\/03331024211024161","article-title":"CGRP measurements in human plasma \u2013 a methodological study","volume":"41","author":"K Messlinger","year":"2021","journal-title":"Cephalalgia"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1111\/j.1526-4610.2006.00294.x","article-title":"Salivary levels of CGRP and VIP in rhinosinusitis and migraine patients","volume":"46","author":"J L Bellamy","year":"2006","journal-title":"Headache: The Journal of Head and Face Pain"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1111\/j.1526-4610.2009.01523.x","article-title":"Elevated saliva calcitonin gene-related peptide levels during acute migraine\n                    predict therapeutic response to rizatriptan","volume":"49","author":"R K Cady","year":"2009","journal-title":"Headache: The Journal of Head and Face Pain"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/j.1601-0825.2010.01717.x","article-title":"Plasma and saliva levels of nerve growth factor and neuropeptides in chronic\n                    migraine patients","volume":"17","author":"M U Jang","year":"2011","journal-title":"Oral diseases"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1046\/j.1468-2982.1990.1001039.x","article-title":"Sensory neuropeptides (substance P, calcitonin gene-related peptide) and\n                    vasoactive intestinal polypeptide in human saliva: their pattern in migraine and\n                    cluster headache","volume":"10","author":"M Nicolodi","year":"1990","journal-title":"Cephalalgia"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1002\/ana.26472","article-title":"Salivary CGRP and erenumab treatment response: towards precision medicine in\n                    migraine","volume":"92","author":"A Alpuente","year":"2022","journal-title":"Annals of Neurology"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1177\/0333102419856640","article-title":"Calcitonin gene-related peptide levels in tear fluid are elevated in migraine\n                    patients compared to healthy controls","volume":"39","author":"K Kamm","year":"2019","journal-title":"Cephalalgia"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1111\/head.13305","article-title":"The CGRP pathway in migraine as a viable target for therapies","volume":"58","author":"L Edvinsson","year":"2018","journal-title":"Headache: The Journal of Head and Face Pain"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1186\/s10194-023-01644-8","article-title":"Mode and site of action of therapies targeting CGRP signaling","volume":"24","author":"A Labastida-Ram\u00edrez","year":"2023","journal-title":"The Journal of Headache and Pain"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1056\/NEJMoa030505","article-title":"Calcitonin gene-related peptide receptor antagonist BIBN 4096 BS for the acute\n                    treatment of migraine","volume":"350","author":"J Olesen","year":"2004","journal-title":"New England Journal of Medicine"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"5697","DOI":"10.1007\/s10072-022-06184-8","article-title":"Gepants \u2013 a long way to cure: a narrative review","volume":"43","author":"C Altamura","year":"2022","journal-title":"Neurological Sciences"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1007\/s11916-023-01142-1","article-title":"A Brief Review of Gepants","volume":"27","author":"D Li","year":"2023","journal-title":"Current Pain and Headache Reports"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1212\/WNL.0000000000000771","article-title":"Randomized controlled trial of the CGRP receptor antagonist telcagepant for\n                    migraine prevention","volume":"83","author":"T W Ho","year":"2014","journal-title":"Neurology"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"2230","DOI":"10.1056\/NEJMoa1813049","article-title":"Ubrogepant for the treatment of migraine","volume":"381","author":"D W Dodick","year":"2019","journal-title":"New England Journal of Medicine"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/S0140-6736(19)31606-X","article-title":"Efficacy, safety, and tolerability of rimegepant orally disintegrating tablet\n                    for the acute treatment of migraine: a randomised, phase 3, double-blind,\n                    placebo-controlled trial","volume":"394","author":"R Croop","year":"2019","journal-title":"The Lancet"},{"key":"ref44","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1111\/head.14389","article-title":"Zavegepant nasal spray for the acute treatment of migraine: A Phase 2\/3\n                    double-blind, randomized, placebo-controlled, dose-ranging trial","volume":"62","author":"R Croop","year":"2022","journal-title":"Headache: The Journal of Head and Face Pain"}],"container-title":["Fortschritte der Neurologie \u00b7 Psychiatrie"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-2331-0783.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,5]],"date-time":"2024-11-05T14:08:54Z","timestamp":1730815734000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-2331-0783"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":38,"journal-issue":{"issue":"07\/08","published-online":{"date-parts":[[2024,7,18]]},"published-print":{"date-parts":[[2024,7]]}},"URL":"https:\/\/doi.org\/10.1055\/a-2331-0783","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0720-4299","1439-3522"],"issn-type":[{"type":"print","value":"0720-4299"},{"type":"electronic","value":"1439-3522"}],"subject":[],"published":{"date-parts":[[2024,7]]}}}